Shares of NantHealth Inc (NYSE:NH) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.25.

A number of equities analysts have recently weighed in on NH shares. Jefferies Group LLC reiterated a “buy” rating and set a $5.00 target price on shares of NantHealth in a research note on Thursday, September 28th. BidaskClub lowered NantHealth from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Zacks Investment Research upgraded NantHealth from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Thursday, October 12th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $6.00 target price (down previously from $8.00) on shares of NantHealth in a research note on Monday, August 21st.

NantHealth (NYSE:NH) opened at 3.86 on Friday. The firm has a 50-day moving average price of $4.27 and a 200 day moving average price of $4.27. The company’s market capitalization is $470.71 million. NantHealth has a 12 month low of $3.67 and a 12 month high of $13.26.

NantHealth (NYSE:NH) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.32). NantHealth had a negative net margin of 267.11% and a negative return on equity of 83.97%. The business had revenue of $26.23 million during the quarter, compared to analyst estimates of $31.28 million. During the same period in the previous year, the business earned ($0.15) earnings per share. The business’s quarterly revenue was down 16.7% on a year-over-year basis. Analysts expect that NantHealth will post ($0.70) EPS for the current year.

In other NantHealth news, COO Ronald Allen Louks sold 26,820 shares of the firm’s stock in a transaction on Friday, October 6th. The stock was sold at an average price of $4.28, for a total transaction of $114,789.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

A number of institutional investors have recently bought and sold shares of NH. Highbridge Capital Management LLC bought a new position in NantHealth during the 1st quarter worth $998,000. National Planning Corp bought a new position in NantHealth during the 2nd quarter worth $473,000. Renaissance Technologies LLC bought a new position in NantHealth during the 1st quarter worth $457,000. Northern Trust Corp increased its stake in NantHealth by 133.9% during the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock worth $643,000 after acquiring an additional 86,955 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in NantHealth by 91.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock worth $717,000 after acquiring an additional 81,024 shares during the period.

TRADEMARK VIOLATION NOTICE: “NantHealth Inc (NH) Receives Average Rating of “Buy” from Analysts” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/28/nanthealth-inc-nh-receives-average-rating-of-buy-from-analysts.html.

NantHealth Company Profile

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.